▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1715 by analyst upside · 2026-08-13
RLAY
Relay Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+33.4%
implied upside to consensus target
Current Price $20.07
Consensus Target $26.77
Bull Target $32.0
Bear Target $20.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
0
Sell
0
52-Week Low $3.31
52-Week High $20.79
YTD Return +145.4%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.56
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.31
52-Week High $20.79
Current Price $20.07
Bear Target $20.0
Bull Target $32.0
● Now $20.07 ● Target $26.77
TRADING DATA
Avg Volume 3.9M
YTD Return +145.4%
Analyst Count 13
Consensus Buy
Upside to Target +33.4%
Last Updated 2026-08-13

ANALYST SUMMARY

Relay Therapeutics, Inc. (RLAY) is currently trading at $20.07 with a Wall Street consensus price target of $26.77, implying potential upside of 33.4% over the next 12 months. 13 analysts currently cover RLAY, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $20.0.

RLAY operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 145.4% year-to-date and is currently trading near the upper end of its 52-week range of $3.31 – $20.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INDV +26.5%
Indivior Pharmaceuticals, Inc.
$5B · P/E 13.9x · Buy
GRFS +37.0%
Grifols, S.A.
$5B · P/E 10.4x · Buy
ACAD +13.8%
ACADIA Pharmaceuticals Inc.
$5B · P/E 13.2x · Buy
OPCH +19.9%
Option Care Health, Inc.
$4B · P/E 18.1x · Buy
CAI +21.3%
Caris Life Sciences, Inc.
$6B · P/E 2.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for RLAY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-05-26 62% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-26 31% win rate (48 calls)
Barclays - Reiterated
Overweight → Overweight 2026-05-20 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-20 Building track record
Raymond James - Reiterated
Strong Buy → Strong Buy 2026-05-19 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-29 31% win rate (48 calls)
Goldman Sachs - Reiterated
Buy → Buy 2026-04-28 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-04-28 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
20/30
Consensus clarity
18/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →